Context Therapeutics Inc. - Common Stock (CNTX)
CUSIP: 21077P108
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 91,741,639
- Total 13F shares
- 68,619,580
- Share change
- -2,786,388
- Total reported value
- $44,959,003
- Price per share
- $0.66
- Number of holders
- 39
- Value change
- -$1,721,044
- Number of buys
- 13
- Number of sells
- 16
Quarterly Holders Quick Answers
What is CUSIP 21077P108?
CUSIP 21077P108 identifies CNTX - Context Therapeutics Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 21077P108:
Top shareholders of CNTX - Context Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MPM BioImpact LLC |
13F
|
Company |
16%
|
14,705,882
|
$9,000,000 | — | 31 Mar 2025 | |
| Deep Track Capital, LP |
13D/G
13F
|
Company |
8.3%
|
7,419,355
|
$7,419,355 | $0 | 31 Mar 2025 | |
| Avidity Partners Management LP |
13F
|
Company |
8.2%
|
7,477,200
|
$4,576,046 | — | 31 Mar 2025 | |
| Nextech Invest, Ltd. |
13F
|
Company |
8.1%
|
7,419,355
|
$4,540,645 | — | 31 Mar 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
8%
|
7,367,906
|
$4,509,158 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13D/G
13F
|
Company |
4.5%
|
4,003,380
|
$4,003,380 | $0 | 31 Mar 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
5.1%
|
4,683,711
|
$2,866,431 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.5%
|
3,253,467
|
$1,991,122 | — | 31 Mar 2025 | |
| Martin A. Lehr |
13D/G
|
Martin Lehr |
2.1%
|
1,595,742
|
$1,595,742 | $0 | 31 Dec 2024 | |
| Blackstone Inc. |
13F
|
Company |
2.7%
|
2,440,330
|
$1,493,482 | — | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
2.1%
|
1,935,484
|
$1,196,807 | — | 31 Mar 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
1.8%
|
1,663,355
|
$1,017,973 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.5%
|
1,361,188
|
$833,047 | — | 31 Mar 2025 | |
| Sio Capital Management, LLC |
13F
|
Company |
1.4%
|
1,328,352
|
$812,951 | — | 31 Mar 2025 | |
| Ally Bridge Group (NY) LLC |
13F
|
Company |
1.3%
|
1,157,448
|
$708,358 | — | 31 Mar 2025 | |
| Allostery Investments LP |
13F
|
Company |
1%
|
950,166
|
$581,502 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.93%
|
848,970
|
$519,570 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.72%
|
660,589
|
$404,280 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.7%
|
639,219
|
$391,419 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.46%
|
425,500
|
$260,406 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.38%
|
351,094
|
$214,870 | — | 31 Mar 2025 | |
| Shay Capital LLC |
13F
|
Company |
0.21%
|
189,853
|
$116,190 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.19%
|
174,309
|
$106,677 | — | 31 Mar 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.18%
|
168,960
|
$103,404 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.17%
|
152,607
|
$93,395 | — | 31 Mar 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.14%
|
125,852
|
$77,021 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.12%
|
113,565
|
$69,502 | — | 31 Mar 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
0.1%
|
90,000
|
$55,080 | — | 31 Mar 2025 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.07%
|
67,631
|
$41,390 | — | 31 Mar 2025 | |
| Clear Harbor Asset Management, LLC |
13F
|
Company |
0.06%
|
57,804
|
$35,376 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.05%
|
48,671
|
$29,787 | — | 31 Mar 2025 | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
0.04%
|
41,216
|
$25,225 | — | 31 Mar 2025 | |
| CAXTON CORP |
13F
|
Company |
0.02%
|
18,403
|
$11,263 | — | 31 Mar 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.02%
|
15,673
|
$9,592 | — | 31 Mar 2025 | |
| CW Advisors, LLC |
13F
|
Company |
0.02%
|
15,000
|
$9,180 | — | 31 Mar 2025 | |
| Tarek Sahmoud |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
35,000
mixed-class rows
|
$8,415 | — | 16 Aug 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
13,304
|
$8,142 | — | 31 Mar 2025 | |
| Cerity Partners LLC |
13F
|
Company |
0.01%
|
10,000
|
$6,120 | — | 31 Mar 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.01%
|
10,000
|
$6,100 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
444
|
$272 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
432
|
$264 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
113
|
$69 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
100
|
$61 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
80
|
$49 | — | 31 Mar 2025 | |
| Ullmann Claudio Dansky |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
174,960
|
— | — | 13 Feb 2025 | |
| Andy Pasternak |
3/4/5
|
Director |
—
class O/S missing
|
138,900
|
— | — | 12 Jun 2025 | |
| Jennifer Evans Stacey |
3/4/5
|
Director |
—
class O/S missing
|
123,500
|
— | — | 12 Jun 2025 | |
| Karen L. Smith |
3/4/5
|
Director |
—
class O/S missing
|
123,500
|
— | — | 12 Jun 2025 | |
| Linda West |
3/4/5
|
Director |
—
class O/S missing
|
123,500
|
— | — | 12 Jun 2025 | |
| Luke Nathaniel Walker |
3/4/5
|
Director |
—
class O/S missing
|
123,500
|
— | — | 12 Jun 2025 |
Institutional Holders of Context Therapeutics Inc. - Common Stock (CNTX) as of Q2 2025
As of 30 Jun 2025,
Context Therapeutics Inc. - Common Stock (CNTX) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
68,619,580 shares.
The largest 10 holders included
MPM BIOIMPACT LLC, Avidity Partners Management LP, Deep Track Capital, LP, Nextech Invest, Ltd., Blue Owl Capital Holdings LP, GREAT POINT PARTNERS LLC, FRANKLIN RESOURCES INC, VANGUARD GROUP INC, Blackstone Inc., and Nantahala Capital Management, LLC.
This page lists
39
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
42
Q2 2025 holders
39
Holder diff
-3
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.